| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/12/2007 | WO2007076619A1 Pharmaceutical composition for the treatment of nail diseases |
| 07/12/2007 | WO2007076601A1 Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof |
| 07/12/2007 | WO2007076572A1 A method of treatment |
| 07/12/2007 | WO2007062874A3 Sulfamoyl sulfonate prodrugs |
| 07/12/2007 | WO2007062107A3 Immunostimulatory oligoribonucleotides |
| 07/12/2007 | WO2007061948A3 Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| 07/12/2007 | WO2007061798A3 Nicotinoyl riboside compositions and methods of use |
| 07/12/2007 | WO2007061739A3 Pharmaceutical compositions comprising buprenorphine |
| 07/12/2007 | WO2007060419A3 Method of preventing oral staining |
| 07/12/2007 | WO2007059257A8 N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| 07/12/2007 | WO2007059103A3 Serum response factor and myocardin control alzheimer cerebral amyloid angiopathy |
| 07/12/2007 | WO2007058992A3 Mutations and polymorphisms of hdac6 |
| 07/12/2007 | WO2007057571A3 3-acylindole derivatives the preparation and the therapeutic use thereof |
| 07/12/2007 | WO2007056618A9 Compositions and methods for the treatment of addiction and other neuropsychiatric disorders |
| 07/12/2007 | WO2007056593A3 α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS |
| 07/12/2007 | WO2007056201A3 THERAPEUTIC AGENT FOR iNOS GENERATING ILLNESS |
| 07/12/2007 | WO2007056091A3 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof |
| 07/12/2007 | WO2007056021A3 5-lipoxygenase-activating protein (flap) inhibitors |
| 07/12/2007 | WO2007055885A3 Pharmaceutical gallium compositions and methods |
| 07/12/2007 | WO2007054719A3 Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| 07/12/2007 | WO2007054279A8 Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| 07/12/2007 | WO2007053865A9 Pharmaceutical use of a compound |
| 07/12/2007 | WO2007053700A3 Use of pyridoxamine to treat and/or prevent disease processes |
| 07/12/2007 | WO2007053639A3 A-type procyanidins and cox-2 expression |
| 07/12/2007 | WO2007053184A3 Methods for producing micrornas |
| 07/12/2007 | WO2007052310A3 Polymorphs of fexofenadine hydrochloride and process for their preparation |
| 07/12/2007 | WO2007052301A3 Process for the preparation of irbesartan |
| 07/12/2007 | WO2007052300A3 Processes for the preparation of different forms of (s)-(+)-clopidogrel besylate |
| 07/12/2007 | WO2007052123A3 Pyrazine derivatives as sodium channel modulators for the treatment of pain |
| 07/12/2007 | WO2007051462A3 Use of tetraorganosilicon compounds |
| 07/12/2007 | WO2007050655A3 Combination of histone deacetylase inhibitors and radiation |
| 07/12/2007 | WO2007050294A3 Liquid dosage forms having enteric properties of delayed and then sustained release |
| 07/12/2007 | WO2007048545A3 Alkoxyalkyl spirocyclic tetramic acids and tetronic acids |
| 07/12/2007 | WO2007048070A3 Pyrrolo-pyridine derivatives for the treatment of cancer diseases |
| 07/12/2007 | WO2007047725A3 Methods for treating disorders associated with hyperlipidemia in a mammal |
| 07/12/2007 | WO2007047577A3 Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders |
| 07/12/2007 | WO2007047575A3 Pharmacological treatments for sleep-related breathing disorders |
| 07/12/2007 | WO2007047323A3 Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subject |
| 07/12/2007 | WO2007047235A3 Compositions and methods for treatment of airway hypersecretion |
| 07/12/2007 | WO2007046868A3 Thiazolidine derivatives and their uses as therapeutic agents |
| 07/12/2007 | WO2007046842A3 Composition for inhibition of cathepsin k |
| 07/12/2007 | WO2007045930A3 Modulation of trpv expression levels |
| 07/12/2007 | WO2007044723A3 Methods for achieving and maintaining weight loss |
| 07/12/2007 | WO2007044318A3 Anti-hypercholesterolemic compounds |
| 07/12/2007 | WO2007044180A3 Improved toleration iron supplement compositions |
| 07/12/2007 | WO2007042899A3 Human microrna targets in hiv genome and a method of identification thereof |
| 07/12/2007 | WO2007042321A3 Kinase inhibitors |
| 07/12/2007 | WO2007041410A3 Sustained release small molecule drug formulation |
| 07/12/2007 | WO2007041294A3 Methods for sensitizing cancer cells to inhibitors |
| 07/12/2007 | WO2007038549B1 Treatment of inflammation and vascular abnormalities of the eye |
| 07/12/2007 | WO2007038459A3 Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
| 07/12/2007 | WO2007038315A3 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
| 07/12/2007 | WO2007038314A3 Fused heterocyclic compounds useful as kinase modulators |
| 07/12/2007 | WO2007038209A3 Fused tetracyclic mglur1 antagonists as therapeutic agents |
| 07/12/2007 | WO2007034503A3 Controlled release dosage formulation of duloxetine |
| 07/12/2007 | WO2007034279A3 C3a antagonists and pharmaceutical compositions thereof |
| 07/12/2007 | WO2007032023A3 A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof |
| 07/12/2007 | WO2007031828A3 Therapeutic pyrrolidines |
| 07/12/2007 | WO2007031265A3 Combinations comprising a vegf receptor inhibitor and a penetration enhancer |
| 07/12/2007 | WO2007029268B1 Stable oxaliplatin formulation |
| 07/12/2007 | WO2007029093A3 Pharmaceutical dosage forms of oxcarbazepine |
| 07/12/2007 | WO2007029078A3 Succinimide and glutarimide derivatives as adrenergic receptor antagonists |
| 07/12/2007 | WO2007029063A3 Treatment and/or prevention of pervasive developmental disorders |
| 07/12/2007 | WO2007029008A3 Method of treatment or prevention of age-related macular degeneration |
| 07/12/2007 | WO2007027780A3 Benzopyran and pyranopyridine derivatives as potassium channel openers |
| 07/12/2007 | WO2007027548A9 Methods of modulating intestinal fluid balance |
| 07/12/2007 | WO2007027236A3 Composition and method for treating nosebleeds |
| 07/12/2007 | WO2007026251A3 Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| 07/12/2007 | WO2007026218A3 Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists |
| 07/12/2007 | WO2007025146A3 Balsalazide formulations and manufacture and use thereof |
| 07/12/2007 | WO2007024651A3 Bridged n-bicyclic sulfonamido inhibitors of gamma secretase |
| 07/12/2007 | WO2007023507A3 Oxazolidinones bearing antimicrobial activity composition and methods of preparation |
| 07/12/2007 | WO2007023395A3 Benzo[b]furane and benzo[b]thiophene derivatives |
| 07/12/2007 | WO2007021991A3 Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| 07/12/2007 | WO2007021937A3 Unsaturated heterocyclic derivatives |
| 07/12/2007 | WO2007020079A3 Orally disintegratable simvastatin tablets |
| 07/12/2007 | WO2007019888A3 Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases |
| 07/12/2007 | WO2007019308A3 Illudin analogs useful as anticancer agents |
| 07/12/2007 | WO2007019098A3 Hiv integrase inhibitors |
| 07/12/2007 | WO2007019078A3 Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/12/2007 | WO2007017240A3 Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids |
| 07/12/2007 | WO2007016379A3 Method for improving cell permeability to foreign particles |
| 07/12/2007 | WO2007016256A3 Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
| 07/12/2007 | WO2007014248A3 Method of reducing food intake |
| 07/12/2007 | WO2007014008A3 Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| 07/12/2007 | WO2007012977A3 Steroid kit and foamable composition and uses thereof |
| 07/12/2007 | WO2007011606A3 USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| 07/12/2007 | WO2007009087A3 Methods and products for treatment of diseases |
| 07/12/2007 | WO2007008994A3 Glutamate aggrecanase inhibitors |
| 07/12/2007 | WO2007008821A3 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation |
| 07/12/2007 | WO2007006550A8 Oligomers of straight-chain and unbranched fatty acids, and medicaments containing the same |
| 07/12/2007 | WO2007005670A3 Natural and synthetic sulfoxide, selenone and selenoxide analogs and polymer conjugated forms thereof for the modulation of angiogenesis |
| 07/12/2007 | WO2007002639A3 Non-nucleoside anti-hepacivirus agents and uses thereof |
| 07/12/2007 | WO2007002457A3 Hydroisoindoline tachykinin receptor antagonists |
| 07/12/2007 | WO2007002308A3 Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| 07/12/2007 | WO2007001067A3 Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
| 07/12/2007 | WO2006138243A3 Inhibition of creatine uptake to promote weight loss |
| 07/12/2007 | WO2006134609A3 Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof |
| 07/12/2007 | WO2006133231A3 Treatment for neurodegenerative diseases |
| 07/12/2007 | WO2006130686A3 Hcv protease inhibitors in combination with food |